Skip to Main Content

Paper Details

FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1.
Breast Cancer Res
22
2021
Author NameAffiliation
Oscar M RuedaCancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge
Carlos CaldasCancer Research UK Cambridge Institute and Department of Oncology, University of Cambridge
  • 1 - 2

Datasets

Release 1.2